Elutia Selects Pete Ligotti as CCO to Lead the Commercial Launch of NXT-41x and Transform Post-Mastectomy Care in the $1.5B U.S. Breast Surgery Market

Stock Information for Elutia Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Elutia Inc.

Elutia to Present at Sidoti's Small-Cap Virtual Investor Conference March 18-19
Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Elutia Reports Fourth Quarter and Full Year 2025 Financial Results; Initiates NXT-41 Regulatory Process
Elutia Regains Compliance with Nasdaq Listing Requirements
Elutia to Report Fourth Quarter 2025 Financial Results on Wednesday, March 11, 2026
Where Purpose Meets Performance: Elutia Earns 2026 Great Place to Work Certification(TM)
Elutia Reports Preliminary Fourth Quarter 2025 Results, Strengthened Financial Position, and Upcoming NXT-41x Milestones
Elutia to Present at Global BioInnovation Forum on NXT-41x Biomatrix Program for Plastic and Reconstructive Surgery

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.